The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
Decoy Therapeutics Inc. pe ratio for the quarter ending 2026-06-30 was -0.27, a change of 66.95 year-over-year.
Decoy Therapeutics Inc. pe ratio for the quarter ending 2026-03-31 was -0.27, a change of 50.46 year-over-year.
Decoy Therapeutics Inc. pe ratio for the quarter ending 2025-12-31 was -0.33, a change of 5.38 year-over-year.
Decoy Therapeutics Inc. pe ratio for the quarter ending 2025-09-30 was -8.31, a change of 66.49 year-over-year.
Decoy Therapeutics Inc. pe ratio for fiscal 2026 was -0.27.
Decoy Therapeutics Inc. pe ratio for fiscal 2025 was -0.33, a change of 5.38 from fiscal 2024.
Decoy Therapeutics Inc. pe ratio for fiscal 2024 was -5.71, a change of 31.03 from fiscal 2023.
Decoy Therapeutics Inc. pe ratio for fiscal 2023 was -36.74, a change of 120.51 from fiscal 2022.